Finanzen von Revvity Inc (RVTY)RVTYRevvity Inc

Revvity, Inc. (RVTY) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Life sciences, accounting for 50.9% of total sales, equivalent to $361.85M. Another important revenue stream is Diagnostics. Understanding this composition is critical for investors evaluating how RVTY navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Revvity, Inc. maintains a gross margin of 57.13%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 17.29%, while the net margin is 7.33%. These profitability ratios, combined with a Return on Equity (ROE) of 3.21%, provide a clear picture of how effectively RVTY converts its operational activities into shareholder value.

In the context of the broader market, RVTY competes directly with industry leaders such as COO and BAX. With a market capitalization of $13.04B, it holds a significant position in the sector. When comparing efficiency, RVTY's gross margin of 57.13% stands against COO's 63.59% and BAX's 35.41%. Such benchmarking helps identify whether Revvity, Inc. is trading at a premium or discount relative to its financial performance.

Revvity's revenue for Q2 2026 was $729.688 million, a slight increase from $720.284 million in the previous year, indicating growth potential despite some profitability challenges. The gross margin has improved to 57.13%, reflecting effective cost management.